HPV Vaccines Market Share, Demand, Production & Forecast Analysis to 2021
The Global HPV Vaccines Market size is segmented on the basis of product type, application, and region. A vaccine used to prevent genital warts, anal cancer, cervical cancer, vulvar cancer, and vaginal cancer caused by certain types of human papillomavirus (HPV). It is also used to prevent lesions that are caused by those viruses and that can lead to anal, cervical, vulvar, or vaginal cancer. Also called human papillomavirus vaccine. Human papillomavirus (HPV) causes cervical cancer, which is the fourth most common cancer in women, with apredictable 266,000 deaths and 528,000 new cases in 2012. A large majority (around 85%) of the global load occurs in the less developed regions, where it accounts for almost 12% of all female cancers.
The Global HPV Vaccines Market size is segmented on the basis of product type, application, and region. A vaccine used to prevent genital warts, anal cancer, cervical cancer, vulvar cancer, and vaginal cancer caused by certain types of human papillomavirus (HPV). It is also used to prevent lesions that are caused by those viruses and that can lead to anal, cervical, vulvar, or vaginal cancer. Also called human papillomavirus vaccine. Human papillomavirus (HPV) causes cervical cancer, which is the fourth most common cancer in women, with apredictable 266,000 deaths and 528,000 new cases in 2012. A large majority (around 85%) of the global load occurs in the less developed regions, where it accounts for almost 12% of all female cancers.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>HPV</strong> <strong>Vaccines</strong> <strong>Market</strong> <strong>Share</strong>, <strong>Demand</strong>, <strong>Production</strong> &<br />
<strong>Forecast</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2021</strong><br />
The Global <strong>HPV</strong> <strong>Vaccines</strong> <strong>Market</strong> size is segmented on the basis of product type, application, and<br />
region. A vaccine used <strong>to</strong> prevent genital warts, anal cancer, cervical cancer, vulvar cancer, and<br />
vaginal cancer caused by certain types of human papillomavirus (<strong>HPV</strong>). It is also used <strong>to</strong> prevent<br />
lesions that are caused by those viruses and that can lead <strong>to</strong> anal, cervical, vulvar, or vaginal cancer.<br />
Also called human papillomavirus vaccine.<br />
The Global <strong>HPV</strong> <strong>Vaccines</strong> <strong>Market</strong> size is segmented on the basis of product type, application, and<br />
region. A vaccine used <strong>to</strong> prevent genital warts, anal cancer, cervical cancer, vulvar cancer, and<br />
vaginal cancer caused by certain types of human papillomavirus (<strong>HPV</strong>). It is also used <strong>to</strong> prevent<br />
lesions that are caused by those viruses and that can lead <strong>to</strong> anal, cervical, vulvar, or vaginal cancer.<br />
Also called human papillomavirus vaccine.<br />
Human papillomavirus (<strong>HPV</strong>) causes cervical cancer, which is the fourth most common cancer in<br />
women, with apredictable 266,000 deaths and 528,000 new cases in 2012. A large majority (around<br />
85%) of the global load occurs in the less developed regions, where it accounts for almost 12% of all<br />
female cancers.<br />
Browse Full Research Report @<br />
https://www.millioninsights.com/industry-reports/human-papillomavirus-hpv-vaccines-market
<strong>HPV</strong> vaccine is an inactivated (not live) vaccine which protects against four major types of <strong>HPV</strong>.<br />
These include two types that cause about 70% of cervical cancer and two types that cause about<br />
90% of genital warts. <strong>HPV</strong> vaccine can prevent most genital warts and most cases of cervical cancer.<br />
Human papillomaviruses (<strong>HPV</strong>s) are a group of more than 200 related viruses. More than 40 <strong>HPV</strong><br />
types can be easily spread through direct sexual contact, from the skin and mucous membranes of<br />
infected people <strong>to</strong> the skin and mucous membranes of their partners. They can be spread by<br />
vaginal, anal, and oral sex. Other <strong>HPV</strong> types are responsible for non-genital warts, which are not<br />
sexually transmitted. There is no treatment for <strong>HPV</strong> infection, but the conditions it causes can be<br />
treated.<br />
Based on type, the <strong>HPV</strong> vaccine market size is classified in<strong>to</strong> Low risk <strong>HPV</strong>s, and High risk <strong>HPV</strong>s. Low<br />
risk <strong>HPV</strong>s, which do not cause cancer but can cause skin warts, precisely known as condylomata<br />
acuminate, are found on or around the genitals and anus. For example, <strong>HPV</strong> types 6 and 11 cause<br />
90% of all genital warts. <strong>HPV</strong> types 6 and 11 also cause recurrent respira<strong>to</strong>ry papilloma<strong>to</strong>sis, a<br />
disease in which benign tumors grow in the air passages leading from the nose and mouth in<strong>to</strong> the<br />
lungs.<br />
High-risk <strong>HPV</strong>s which can cause cancer. About a dozen high-risk <strong>HPV</strong> types have been identified.<br />
Two of these, <strong>HPV</strong> types 16 and 18, are responsible for most <strong>HPV</strong>-caused cancers. On the basis of<br />
vaccines, the global market size is classified in<strong>to</strong> bivalent and a quadrivalent vaccine. Both vaccines<br />
are highly effective in preventing infection with virus types 16 and 18, which are <strong>to</strong>gether<br />
responsible for almost 70% of cervical cancer cases globally. The vaccines are also highly effective in<br />
preventing precancerous cervical lesions caused by these virus types.<br />
Request Sample Copy of this <strong>Market</strong> Research @ https://www.millioninsights.com/industryreports/human-papillomavirus-hpv-vaccines-market/request-sample<br />
The quadrivalent vaccine is also highly effective in avertinganogenital warts, a common genital<br />
disease which is practically always caused by infection with <strong>HPV</strong> types 6 and 11. Data from clinical<br />
trials and initial post-marketing surveillance conducted in several continents show both vaccines <strong>to</strong><br />
be safe. On the basis of application, the <strong>HPV</strong> vaccines market size is classified in<strong>to</strong> pediatric, adult,<br />
and others.<br />
Geographically, the <strong>HPV</strong> vaccines market size is segmented in<strong>to</strong> North America, China, Europe,<br />
Japan, India, and Southeast Asia. North America and Europe accounts for the maximum market<br />
share of the global <strong>HPV</strong> vaccines market and is expected <strong>to</strong> grow at highest CAGR during the
forecast period. This is due <strong>to</strong> the governments from major countries of these regions having<br />
publicly funded <strong>HPV</strong> vaccination.<br />
The key players in the <strong>HPV</strong> vaccines market include Astellas Pharma Inc, CSL Limited, Emergent<br />
BioSolutions, Inc, GlaxoSmithKline, Johnson & Johnson, MedImmune, LLC, Merck & Co, Pfizer, Sanofi<br />
Pasteur, Serum Institute, and India Pvt. Ltd.<br />
<strong>Market</strong> Segment:<br />
This report studies <strong>HPV</strong> <strong>Vaccines</strong> in Global market, especially in North America, Europe, China,<br />
Japan, India and Southeast Asia, focuses on <strong>to</strong>p manufacturers in global market, with sales, price,<br />
revenue and market share for each manufacturer, covering<br />
• Astellas Pharma Inc<br />
• CSL Limited<br />
• Emergent BioSolutions, Inc<br />
• GlaxoSmithKline<br />
• Johnson & Johnson<br />
• MedImmune, LLC<br />
• Merck & Co<br />
• Pfizer<br />
• Sanofi Pasteur<br />
• Serum Institute<br />
• India Pvt. Ltd. (India)<br />
See More Reports of this Category by Million Insights @<br />
https://www.millioninsights.com/industry/pharmaceuticals
<strong>Market</strong> Segment by Region, this report splits Global in<strong>to</strong> several key Regions, with sales, revenue,<br />
market share and growth rate of <strong>HPV</strong> <strong>Vaccines</strong> in these regions, from 2011 <strong>to</strong> <strong>2021</strong> (forecast), like<br />
• North America<br />
• China<br />
• Europe<br />
• Japan<br />
• India<br />
• Southeast Asia<br />
Split by product type, with sales, revenue, price, market share and growth rate of each type, can<br />
be divided in<strong>to</strong><br />
• Type I<br />
• Type II<br />
• Type III<br />
Split by application, this report focuses on sales, market share and growth rate of <strong>HPV</strong> <strong>Vaccines</strong> in<br />
each application, can be divided in<strong>to</strong><br />
• Pediatric<br />
• Adult<br />
• Application 3<br />
Browse Full Research Report @<br />
https://www.millioninsights.com/industry-reports/human-papillomavirus-hpv-vaccines-market
Get in <strong>to</strong>uch<br />
At Million Insights, we work with the aim <strong>to</strong> reach the highest levels of cus<strong>to</strong>mer satisfaction.<br />
Our representatives strive <strong>to</strong> understand diverse client requirements and cater <strong>to</strong> the same with the<br />
most innovative and functional solutions.<br />
Contact Person:<br />
Ryan Manuel<br />
Research Support Specialist, USA<br />
Email: ryan@millioninsights.com<br />
Global Headquarters<br />
Million Insights<br />
Fel<strong>to</strong>n Office Plaza 6265 Highway 9<br />
Fel<strong>to</strong>n, California 95018, United States<br />
Phone: 1-408-610-2300<br />
Email: sales@millioninsights.com<br />
Asia Pacific<br />
Million Insights<br />
Office No. 302, 3rd Floor, Manikchand<br />
Galleria, Model Colony, Shivaji Nagar,<br />
Pune, MH, 411016 India<br />
Phone: 91-20-65300184<br />
Email: sales@millioninsights.com<br />
Visit Our Blog:www.millioninsights.blogspot.com
Change language